Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
The study population will include individuals with known prostate cancer and controls without prostate cancer. Individuals in the study population will be of Arab descent from Qatar. In this protocol, researchers will survey epidemiologic factors and medical records of patients with prostate cancer in order to study the clinical characteristics of these individuals. The researchers will collect blood and tissue samples to evaluate the genetic characteristics of individuals with prostate cancer. The researchers will also collect blood samples of individuals without prostate cancer to serve as a control. The goal will be to identify genes that are associated with prostate cancer and gene profiles that are associated with differing prognoses in individuals who have prostate cancer.
Age
40–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
All study subjects should be able to provide informed consent
Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)
Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer
All study subjects should be able to provide informed consent
Males ages 40 years or older
Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.
Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care
Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0
You may not be if
Individuals with family history of prostate cancer
Individuals not deemed in good overall health by the investigator will not be accepted into the study
Patient refuses consent
Clareo Health | Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab Countries
